Xiaomi Shares Jump on Europe EV Expansion Plan 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
OpenAI Nears Astra AI Model Launch With Safety Focus 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Add as a preferred source on Google
BURNABY, British Columbia, Feb. 28, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 financial and operating results after the close of U.S. financial markets on Wednesday, March 7, 2018. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.
To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 5578516. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Vice President, Corporate Affairs & Investor Relations
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]
